FLT3変異型AMLにおける移植後再発のギルテリチニブによる管理 | Rzetelska | Acta Haematologica Polonica – Via Medica Journals
Managing post-transplant relapse in FLT3-mutated AML with gilteritinib | Rzetelska | Acta Haemat…
医薬品情報と治療ガイド
現在販売中の商品に関連する医薬品情報、適応症、用法用量、安全上の注意を掲載しています。
Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised
Retsevmo is a cancer medicine for use in patients whose cancer is caused by certain changes in a…
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authoris…
